Johnson & Johnson (NYSE: JNJ) and Legend Biotech Corporation (Nasdaq: LEGN) have reported unusually long treatment-free disease control with Carvykti in relapsed or refractory multiple myeloma, with half of a small Phase 2 cohort remaining alive and progression-free five years after receiving a single infusion and no maintenance treatment. The new CARTITUDE-2 Cohort A analysis followed 20 patients who had previously received one to three treatment lines and were refractory to lenalidomide, providing one of the clearest long-term signals yet supporting the strategy of moving BCMA-directed CAR-T therapy earlier in multiple myeloma.
At a median follow-up of 60.7 months, 10 of the 20 patients remained alive without disease progression, median progression-free survival reached 60.5 months and the estimated five-year overall survival rate was 69.2%. All patients received only the original ciltacabtagene autoleucel infusion without maintenance therapy. Johnson & Johnson presented the results at the International Myeloma Society Annual Meeting in Glasgow on September 25.
The numbers are striking, but the study size demands restraint. Twenty patients cannot establish how frequently five-year treatment-free remission will occur across the much broader multiple myeloma population, and CARTITUDE-2 was not a randomized trial comparing Carvykti with another active second-line regimen. The data instead provide a long-duration signal that becomes particularly interesting when viewed alongside larger randomized Carvykti trials that have already established earlier-line efficacy.
Why do five treatment-free years matter so much in relapsed multiple myeloma?
Multiple myeloma has traditionally been managed as a chronic, incurable blood cancer characterized by repeated cycles of treatment, remission and eventual relapse. Patients can move through proteasome inhibitors, immunomodulatory medicines, anti-CD38 antibodies, bispecific antibodies, CAR-T therapy and other combinations, with remissions generally becoming harder to sustain as successive treatment lines accumulate.
That makes treatment-free remission qualitatively different from simply extending progression-free survival while a patient continues taking therapy. Many modern myeloma regimens are administered continuously until progression or intolerance, meaning strong disease control can still involve regular clinic visits, injections, infusions, oral medicines, infection monitoring and ongoing adverse effects.
Carvykti follows another model. A patient’s T cells are collected, genetically modified to recognize B-cell maturation antigen, expanded and then returned through a single infusion. If those engineered cells generate sufficiently deep and durable disease control, patients may spend long periods without maintenance treatment.
In CARTITUDE-2 Cohort A, that possibility persisted to the five-year mark for half of the studied patients. The result does not prove those patients are cured, and Johnson & Johnson’s references to potential curative outcomes remain an interpretation of emerging evidence rather than an established clinical conclusion. It does show that prolonged remission without continuous anti-myeloma treatment is possible for a meaningful proportion of this small earlier-line cohort.
Does treating patients earlier make Carvykti work better?
The biological logic is compelling. Patients earlier in their disease course generally have T cells exposed to fewer rounds of chemotherapy and other immunosuppressive treatments. Their immune cells may therefore be fitter when collected and engineered into a CAR-T product.
Tumor biology can also become increasingly complicated after repeated therapy. Successive treatment lines create selective pressure that can leave behind more resistant clones, while patients accumulate organ damage, infections, cytopenias and declining physical reserve.
CARTITUDE-2 Cohort A enrolled patients after only one to three previous treatment lines. That is substantially earlier than the heavily pretreated population in which Carvykti was initially developed and approved.
The five-year data are consistent with the hypothesis that moving CAR-T earlier may allow deeper and longer-lasting disease control, but the comparison cannot be proven from CARTITUDE-2 alone because the study was not designed to randomize early treatment against late treatment. Larger studies such as CARTITUDE-4 have provided the more rigorous evidence supporting earlier use, while the latest CARTITUDE-2 analysis adds unusually long follow-up to that strategy.
Carvykti is already approved in the United States for adults with relapsed or refractory multiple myeloma after at least one prior treatment line that included a proteasome inhibitor and an immunomodulatory agent, provided the disease is refractory to lenalidomide. The FDA expanded the indication into this earlier setting in April 2024.
What does MRD negativity tell us about the patients still progression-free?
Minimal residual disease testing looks for extremely small numbers of remaining cancer cells that conventional clinical assessments can miss. Achieving MRD negativity at high sensitivity is associated with deeper treatment responses in multiple myeloma, although it still does not guarantee that the disease will never return.
At the five-year assessment, bone marrow MRD testing was available for only three patients because testing was not mandated by the protocol at that point. All three were MRD-negative at a sensitivity of 10^-6, meaning testing detected no malignant cells down to approximately one myeloma cell among one million assessed cells.
The sample is too small to extrapolate broadly, but it supports the biological plausibility of the long remissions. Patients remaining progression-free were not merely maintaining stable measurable disease in every case; at least those evaluated by highly sensitive bone marrow testing continued to have no detectable residual myeloma.
High-risk disease also did not exclude durable benefit in this tiny cohort. Five of the 10 patients who were alive and progression-free at five years had at least one high-risk cytogenetic abnormality, and four carried two or more high-risk features. That is potentially important because high-risk cytogenetics have historically been associated with faster relapse and poorer long-term outcomes.
What safety risks remain with Carvykti despite the long remissions?
CAR-T therapy can produce profound efficacy, but the treatment is not a low-risk alternative to chronic medication.
Carvykti carries warnings involving cytokine release syndrome, neurological toxicities, prolonged or recurrent cytopenias, hemophagocytic lymphohistiocytosis or macrophage activation syndrome and secondary hematological malignancies. Manufacturing also requires collection of an individual patient’s cells and time to produce the personalized therapy, making access more complicated than receiving an off-the-shelf drug.
Johnson & Johnson said the five-year CARTITUDE-2 follow-up did not reveal new CAR-T-related neurotoxicity. Since the previous analysis, however, one patient developed acute myeloid leukemia, while two additional deaths were reported, one following progressive multiple myeloma and another associated with a new cancer.
Those findings reinforce why long-term follow-up is particularly important for cellular therapies. A treatment capable of producing years without maintenance must still be evaluated against delayed toxicities that can emerge long after the acute CAR-T treatment period.
The risk-benefit calculation may nevertheless look different when CAR-T is administered earlier. A patient receiving therapy while physically fitter may tolerate treatment differently from someone who has already undergone five or six regimens, although that premise also requires continued prospective evidence.
Why is Carvykti becoming financially important to Johnson & Johnson?
Carvykti is rapidly moving from a specialist cellular therapy into a meaningful oncology growth franchise.
Johnson & Johnson reported worldwide Carvykti sales of $657 million in the second quarter of 2026, up 49.4% from $439 million a year earlier. United States sales increased to $472 million from $358 million, while international revenue more than doubled to $185 million from $81 million.
That places Carvykti on an annualized quarterly revenue run rate above $2.6 billion before considering additional expansion in patient eligibility, manufacturing capacity or geographic adoption.
The therapy also sits inside an unusually broad Johnson & Johnson multiple myeloma portfolio. Darzalex generated $4.21 billion during the second quarter, while Tecvayli and Talvey provide off-the-shelf bispecific options targeting BCMA and GPRC5D. Johnson & Johnson can therefore participate across several points in the myeloma pathway rather than depending on one modality.
For Carvykti specifically, moving treatment earlier can have a disproportionate commercial effect. More patients remain eligible earlier in disease, and fewer are lost to deterioration or death before reaching cellular therapy. The constraint becomes manufacturing capacity, treatment-center availability and physician sequencing rather than simply proving the drug works.
How does Legend Biotech benefit from the same Carvykti growth story?
Carvykti originated through Legend Biotech’s collaboration with Johnson & Johnson, established in 2017 to jointly develop and commercialize ciltacabtagene autoleucel. That makes Carvykti far more central to Legend Biotech’s valuation than it is to diversified Johnson & Johnson.
Legend Biotech shares closed at $19.11 on September 25, up 0.26% for the session after gaining 3.31% a day earlier. The stock had risen more than 8% over five trading days but remained approximately 12% lower year to date and around 42% below its level one year earlier, indicating that investors continue weighing Carvykti growth against broader questions around costs, manufacturing expansion and the company’s dependence on its flagship therapy.
Johnson & Johnson shares closed around $269.80 on September 25, down roughly 0.3% for the day after gaining 0.6% in the previous session. The muted reaction is unsurprising because Carvykti represents only one component of a healthcare company expected to generate more than $100 billion of revenue in 2026.
For Legend Biotech, by contrast, every improvement in Carvykti’s long-term competitive positioning can materially affect the investment case.
Could Carvykti eventually challenge the idea that multiple myeloma is always incurable?
That is the most provocative question raised by the five-year data, and it requires the most careful answer.
Ten patients remaining alive and progression-free for five years without maintenance treatment is an outcome that would have been difficult to achieve historically in relapsed multiple myeloma. The presence of MRD negativity among the few patients tested makes the result even more intriguing.
Yet a 20-patient Phase 2 cohort cannot establish cure. Relapses can occur beyond five years, and larger patient populations may produce materially different results. CAR-T also carries serious acute and long-term risks that prevent the therapy from being treated as a simple one-time solution.
The more defensible conclusion is that Carvykti is pushing the treatment objective higher. Instead of asking only how many additional months can be added before the next relapse, researchers can increasingly ask whether selected patients treated early enough can achieve remission measured in many years without ongoing therapy.
For Johnson & Johnson and Legend Biotech, that possibility has both clinical and commercial significance. Carvykti is already growing at nearly 50% annually, and the latest CARTITUDE-2 follow-up gives physicians another reason to consider whether cellular therapy belongs closer to the beginning of the relapsed myeloma pathway rather than being reserved until conventional options are exhausted.
The next question is no longer whether Carvykti can produce deep responses. It is how many patients can reproduce the extraordinary durability seen in this small cohort when the therapy is deployed earlier and at much greater scale.
